<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2021-5-14-19</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1660</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LECTURES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕКЦИЯ</subject></subj-group></article-categories><title-group><article-title>Antiplatelet therapy in stroke prevention after non-cardioembolic transient ischemic attack</article-title><trans-title-group xml:lang="ru"><trans-title>Антитромбоцитарная терапия в профилактике инсульта после транзиторной ишемической атаки некардиоэмболического генеза</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фонякин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fonyakin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андрей Викторович Фонякин</p><p>2-е неврологическое отделение</p><p>125367, Москва, Волоколамское шоссе, 80</p></bio><bio xml:lang="en"><p>Andrey Viktorovich Fonyakin</p><p>Second Neurological Department</p><p>80, Volokolamskoe Shosse, Moscow 125367</p></bio><email xlink:type="simple">fonyakin@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гераскина</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Geraskina</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>2-е неврологическое отделение</p><p>125367, Москва, Волоколамское шоссе, 80</p></bio><bio xml:lang="en"><p>Second Neurological Department</p><p>80, Volokolamskoe Shosse, Moscow 125367</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимова</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimova</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>2-е неврологическое отделение</p><p>125367, Москва, Волоколамское шоссе, 80</p></bio><bio xml:lang="en"><p>Second Neurological Department</p><p>80, Volokolamskoe Shosse, Moscow 125367</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научный центр неврологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Center of Neurology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>16</day><month>10</month><year>2021</year></pub-date><volume>13</volume><issue>5</issue><fpage>14</fpage><lpage>19</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Fonyakin A.V., Geraskina L.A., Maksimova M.Y., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Фонякин А.В., Гераскина Л.А., Максимова М.Ю.</copyright-holder><copyright-holder xml:lang="en">Fonyakin A.V., Geraskina L.A., Maksimova M.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1660">https://nnp.ima-press.net/nnp/article/view/1660</self-uri><abstract><p>The review shows modern concepts on the role of antiplatelet therapy in the secondary prevention of cardiovascular diseases in patients after non-cardioembolic ischemic stroke or transient ischemic attack (TIA). We present an analytical characteristic of all antiplatelet agents that have been studied in randomized controlled trials worldwide. We demonstrate the advantages and disadvantages of each agent in monotherapy and in combination. New ideas about the rationality of the use of combined antiplatelet therapy with clopidogrel and acetylsalicylic acid in the first 24 hours and no more than 90 days in patients with minor ischemic stroke or TIA are discussed. The efficacy and safety of new antiplatelet agents are analyzed. The basic principles of choosing antiplatelet agents in patients after ischemic noncardioembolic stroke/TIA are outlined.</p></abstract><trans-abstract xml:lang="ru"><p>В статье показаны современные представления о роли антитромбоцитарной терапии во вторичной профилактике сердечно-сосудистых заболеваний у пациентов, перенесших некардиоэмболический ишемический инсульт либо транзиторную ишемическую атаку (ТИА). На основе данных доказательной медицины представлена аналитическая характеристика всех тромбоцитарных антиагрегантов, прошедших клинические испытания в мире. Продемонстрированы преимущества и несовершенства каждого средства как в монотерапии, так и при комбинированном использовании. Отражены новые представления о рациональности применения комбинированной антитромбоцитарной терапии клопидогрелом и ацетилсалициловой кислотой в первые 24 ч и продолжительностью не более 90 дней у больных с малым ишемическим инсультом либо ТИА. Анализируются эффективность и безопасность новых тромбоцитарных антиагрегантов. Изложены основные принципы выбора антитромбоцитарных средств у пациентов после ишемического некардиоэмболического инсульта.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>антитромбоцитарная терапия</kwd><kwd>транзиторная ишемическая атака</kwd><kwd>некардиоэмболический инсульт</kwd><kwd>вторичная профилактика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>antiplatelet therapy</kwd><kwd>transient ischemic attack</kwd><kwd>noncardioembolic stroke</kwd><kwd>secondary prevention</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. Stroke. 2009 Jun;40(6):2276-93. doi: 10.1161/STROKEAHA.108.192218. Epub 2009 May 7.</mixed-citation><mixed-citation xml:lang="en">Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. Stroke. 2009 Jun;40(6):2276-93. doi: 10.1161/STROKEAHA.108.192218. Epub 2009 May 7.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Стаховская ЛВ, редактор. Клинические рекомендации по ведению больных с ишемическим инсультом и транзиторными ишемическими атаками. Москва: МЕДпресс-информ; 2017. 208 с.</mixed-citation><mixed-citation xml:lang="en">Stakhovskaya LV, editor. Klinicheskiye rekomendatsii po vedeniyu bol'nykh s ishemicheskim insul'tom i tranzitornymi ishemicheskimi atakami [Clinical guidelines for the management of patients with ischemic stroke and transient ischemic attacks]. Moscow: MEDpressinform; 2017. 208 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of transient ischemic attack. JAMA. 2000 Dec 13;284(22):2901-6. doi: 10.1001/jama.284.22.2901</mixed-citation><mixed-citation xml:lang="en">Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of transient ischemic attack. JAMA. 2000 Dec 13;284(22):2901-6. doi: 10.1001/jama.284.22.2901</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Johnston SC, Nguyen-Huynh MN, Schwarz ME, et al. National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol. 2006 Sep;60(3):301-13. doi: 10.1002/ana.20942</mixed-citation><mixed-citation xml:lang="en">Johnston SC, Nguyen-Huynh MN, Schwarz ME, et al. National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol. 2006 Sep;60(3):301-13. doi: 10.1002/ana.20942</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457-507. doi: 10.1159/000131083. Epub 2008 May 6.</mixed-citation><mixed-citation xml:lang="en">European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457-507. doi: 10.1159/000131083. Epub 2008 May 6.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Гераскина ЛА, Фонякин АВ. Транзиторные ишемические атаки. Современный взгляд на актуальную проблему. Трудный пациент. 2011;(5):28-32.</mixed-citation><mixed-citation xml:lang="en">Geraskina LA, Fonyakin AV. Transient ischemic attacks. A modern view of the current problem. Trudnyy patsiyent. 2011;(5):28-32 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rothwell PM, Giles MF, Flossmann E, et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet. 2005 Jul 2-8;366(9479):29-36. doi: 10.1016/S0140-6736(05)66702-5</mixed-citation><mixed-citation xml:lang="en">Rothwell PM, Giles MF, Flossmann E, et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet. 2005 Jul 2-8;366(9479):29-36. doi: 10.1016/S0140-6736(05)66702-5</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007 Jan 27;369(9558):283-92. doi: 10.1016/S0140-6736(07)60150-0</mixed-citation><mixed-citation xml:lang="en">Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007 Jan 27;369(9558):283-92. doi: 10.1016/S0140-6736(07)60150-0</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. doi: 10.1161/STR.0000000000000158. Epub 2018 Jan 24.</mixed-citation><mixed-citation xml:lang="en">Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. doi: 10.1161/STR.0000000000000158. Epub 2018 Jan 24.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Суслина ЗА, Фонякин АВ, Кузнецов АЛ. Кардиоэмболический инсульт: источники эмболии и пути профилактики. Атмосфера. Новости кардиологии. 2004;(2):13-6.</mixed-citation><mixed-citation xml:lang="en">Suslina ZA, Fonyakin AV, Kuznetsov AL. Cardioembolic stroke: sources of embolism and ways of prevention. Atmosfera. Novosti kardiologii. 2004;(2):13-6 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Purroy F, Montaner J, Molina CA, et al. Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke. 2007 Dec;38(12):3225-9. doi: 10.1161/STROKEAHA.107.488833</mixed-citation><mixed-citation xml:lang="en">Purroy F, Montaner J, Molina CA, et al. Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke. 2007 Dec;38(12):3225-9. doi: 10.1161/STROKEAHA.107.488833</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi: 10.1161/STR.0000000000000375</mixed-citation><mixed-citation xml:lang="en">Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi: 10.1161/STR.0000000000000375</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Naqvi IA, Kamal AK, Rehman H. Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2020 Aug 17;8(8):CD009716. doi: 10.1002/14651858.CD009716.pub2</mixed-citation><mixed-citation xml:lang="en">Naqvi IA, Kamal AK, Rehman H. Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2020 Aug 17;8(8):CD009716. doi: 10.1002/14651858.CD009716.pub2</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Chimowitz MI, Lynn MJ, Howlett-Smith H, et al; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005 Mar 31;352(13):1305-16. doi: 10.1056/NEJMoa043033</mixed-citation><mixed-citation xml:lang="en">Chimowitz MI, Lynn MJ, Howlett-Smith H, et al; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005 Mar 31;352(13):1305-16. doi: 10.1056/NEJMoa043033</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Chimowitz MI, Lynn MJ, Derdeyn CP, et al; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011 Sep 15;365(11):993-1003. doi: 10.1056/NEJMoa1105335. Epub 2011 Sep 7.</mixed-citation><mixed-citation xml:lang="en">Chimowitz MI, Lynn MJ, Derdeyn CP, et al; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011 Sep 15;365(11):993-1003. doi: 10.1056/NEJMoa1105335. Epub 2011 Sep 7.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Collaborative overview of randomised trials of antiplatelet therapy: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994 Jan 8;308(6921):81-106.</mixed-citation><mixed-citation xml:lang="en">Collaborative overview of randomised trials of antiplatelet therapy: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994 Jan 8;308(6921):81-106.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86. doi: 10.1136/bmj.324.7329.71</mixed-citation><mixed-citation xml:lang="en">Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86. doi: 10.1136/bmj.324.7329.71</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">He J, Whelton P, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998 Dec 9;280(22):1930-5. doi: 10.1001/jama.280.22.1930</mixed-citation><mixed-citation xml:lang="en">He J, Whelton P, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998 Dec 9;280(22):1930-5. doi: 10.1001/jama.280.22.1930</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med. 2016 Jul 7;375(1):35-43. doi: 10.1056/NEJMoa1603060. Epub 2016 May 10.</mixed-citation><mixed-citation xml:lang="en">Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med. 2016 Jul 7;375(1):35-43. doi: 10.1056/NEJMoa1603060. Epub 2016 May 10.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Amarenco P, Albers GW, Denison H, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16:301-10. doi: 10.1016/S1474-4422(17)30038-8</mixed-citation><mixed-citation xml:lang="en">Amarenco P, Albers GW, Denison H, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16:301-10. doi: 10.1016/S1474-4422(17)30038-8</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996 Nov 16;348(9038):1329-39. doi: 10.1016/s0140-6736(96)09457-3</mixed-citation><mixed-citation xml:lang="en">CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996 Nov 16;348(9038):1329-39. doi: 10.1016/s0140-6736(96)09457-3</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Costa J, Ferro JM, Matias-Guiu J, et al. Trifluzal for preventing serious vascular events in people at high risk. Stroke. 2005 Jul 20;(3):CD004296. doi: 10.1002/14651858.CD004296.pub2</mixed-citation><mixed-citation xml:lang="en">Costa J, Ferro JM, Matias-Guiu J, et al. Trifluzal for preventing serious vascular events in people at high risk. Stroke. 2005 Jul 20;(3):CD004296. doi: 10.1002/14651858.CD004296.pub2</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized double blind pilot study. Lancet Neurol. 2008 Jun;7(6):494-9. doi: 10.1016/S1474-4422(08)70094-2. Epub 2008 May 2.</mixed-citation><mixed-citation xml:lang="en">Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized double blind pilot study. Lancet Neurol. 2008 Jun;7(6):494-9. doi: 10.1016/S1474-4422(08)70094-2. Epub 2008 May 2.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Shinohara Y, Nishimaru K, Sawada T, et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS). Stroke. 2008 Jun;39(6):1827-33. doi: 10.1161/STROKEAHA.107.505131. Epub 2008 Apr 3.</mixed-citation><mixed-citation xml:lang="en">Shinohara Y, Nishimaru K, Sawada T, et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS). Stroke. 2008 Jun;39(6):1827-33. doi: 10.1161/STROKEAHA.107.505131. Epub 2008 Apr 3.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kennedy J, Ryckborst KJ, Eliasziw M, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol. 2007 Nov;6(11):961-9. doi: 10.1016/S1474-4422(07)70250-8. Epub 2007 Oct 10.</mixed-citation><mixed-citation xml:lang="en">Kennedy J, Ryckborst KJ, Eliasziw M, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol. 2007 Nov;6(11):961-9. doi: 10.1016/S1474-4422(07)70250-8. Epub 2007 Oct 10.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient ischemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet. 2007 Oct 20;370(9596):1432-42. doi: 10.1016/S0140-6736(07)61448-2</mixed-citation><mixed-citation xml:lang="en">Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient ischemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet. 2007 Oct 20;370(9596):1432-42. doi: 10.1016/S0140-6736(07)61448-2</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Танашян ММ, Домашенко МА. Применение курантила при цереброваскулярных заболеваниях. Атмосфера. Нервные болезни. 2005;(3):8-11.</mixed-citation><mixed-citation xml:lang="en">Tanashyan MM, Domashenko MA. The use of curantile for cerebrovascular diseases. Atmosfera. Nervnyye bolezni. 2005;(3):8-11 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2 (ESPS2). Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 Nov;143(1-2):1-13. doi: 10.1016/s0022-510x(96)00308-5</mixed-citation><mixed-citation xml:lang="en">Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2 (ESPS2). Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 Nov;143(1-2):1-13. doi: 10.1016/s0022-510x(96)00308-5</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, et al. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007 Feb;6(2):115-24. doi: 10.1016/S1474-4422(06)70685-8</mixed-citation><mixed-citation xml:lang="en">ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, et al. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007 Feb;6(2):115-24. doi: 10.1016/S1474-4422(06)70685-8</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a metaanalysis. Stroke. 2008;39(4):1358-63. doi: 10.1161/STROKEAHA.107.496281</mixed-citation><mixed-citation xml:lang="en">Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a metaanalysis. Stroke. 2008;39(4):1358-63. doi: 10.1161/STROKEAHA.107.496281</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Guiraud-Chaumeil B, Rascol A, David J, et al. Prevention des recidives des accidents vasculaires cerebraux ischemiques par les antiagregants plaquettaires: resultants d'un essai therapique controle de 3 ans. Rev Neurol. 1982;138(5):367-85.</mixed-citation><mixed-citation xml:lang="en">Guiraud-Chaumeil B, Rascol A, David J, et al. Prevention des recidives des accidents vasculaires cerebraux ischemiques par les antiagregants plaquettaires: resultants d'un essai therapique controle de 3 ans. Rev Neurol. 1982;138(5):367-85.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Bousser MG, Eschwege E, Haguenau M, et al. «AICLA» controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke. Jan-Feb 1983;14(1):5-14. doi: 10.1161/01.str.14.1.5</mixed-citation><mixed-citation xml:lang="en">Bousser MG, Eschwege E, Haguenau M, et al. «AICLA» controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke. Jan-Feb 1983;14(1):5-14. doi: 10.1161/01.str.14.1.5</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">American-Canadian Cooperative Study Group. Persantine aspirin trial in cerebral ischemia, part II: endpoint results. Stroke. May-Jun 1985;16(3):406-15. doi: 10.1161/01.str.16.3.406</mixed-citation><mixed-citation xml:lang="en">American-Canadian Cooperative Study Group. Persantine aspirin trial in cerebral ischemia, part II: endpoint results. Stroke. May-Jun 1985;16(3):406-15. doi: 10.1161/01.str.16.3.406</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Johnston SC, Easton JD, Farrant M, et al.; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018 Jul 19;379(3):215-25. doi: 10.1056/NEJMoa1800410. Epub 2018 May 16.</mixed-citation><mixed-citation xml:lang="en">Johnston SC, Easton JD, Farrant M, et al.; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018 Jul 19;379(3):215-25. doi: 10.1056/NEJMoa1800410. Epub 2018 May 16.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013 Jul 4;369(1):11-9. doi: 10.1056/NEJMoa1215340. Epub 2013 Jun 26.</mixed-citation><mixed-citation xml:lang="en">Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013 Jul 4;369(1):11-9. doi: 10.1056/NEJMoa1215340. Epub 2013 Jun 26.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Ge F, Lin H, Liu Y, et al. Dual antiplatelet therapy after stroke or transient ischaemic attack – how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. Eur J Neurol. 2016 Jun;23(6):1051-7. doi: 10.1111/ene.12982. Epub 2016 Mar 28.</mixed-citation><mixed-citation xml:lang="en">Ge F, Lin H, Liu Y, et al. Dual antiplatelet therapy after stroke or transient ischaemic attack – how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. Eur J Neurol. 2016 Jun;23(6):1051-7. doi: 10.1111/ene.12982. Epub 2016 Mar 28.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Johnston SC, Amarenco P, Denison H, et al; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020 Jul 16;383(3):207-17. doi: 10.1056/NEJMoa1916870</mixed-citation><mixed-citation xml:lang="en">Johnston SC, Amarenco P, Denison H, et al; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020 Jul 16;383(3):207-17. doi: 10.1056/NEJMoa1916870</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
